Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3409038 | 0.97 | MEN1 (0.37) | MEN1KMT2ACYP2D6ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4104974 | 0.97 | MEN1 (0.37) | MEN1KMT2ACYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL13638116 | 0.92 | MEN1 (0.35) | MEN1KMT2ACYP2D6MAPK1 | |
| SCHEMBL24065040 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL4103697 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL3408929 | 0.89 | — | — | |
| SCHEMBL15847181 | 0.81 | OGFRL1 (0.38) | OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL880919 | 0.81 | OGFRL1 (0.35) | OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL12436681 | 0.81 | OGFRL1 (0.38) | OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL16743560 | 0.81 | OGFRL1 (0.38) | OPRM1OPRK1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-15 | — | — | US | disclosed |
| US-20180319794-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| US-10052312-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-21 | — | — | US | disclosed |
| EP-3272749-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-20170182014-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-29 | — | — | US | disclosed |
| EP-2914594-B1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | Bayer Pharma AG (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-9624214-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20150274719-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-01 | — | — | US | disclosed |
| US-9126998-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | Bayer Pharma AG (DE) | 2015-09-08 | — | — | US | disclosed |
| US-20140179672-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAICS | MEN1 2194/4885KMT2A 1080/4885CYP2D6 495/4885 |
| US-20140179672-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAICS | MEN1 2194/4885KMT2A 1080/4885CYP2D6 495/4885 |
| US-10052312-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAICS | MEN1 2194/4885KMT2A 1080/4885CYP2D6 495/4885 |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | MEN1 2194/4885KMT2A 1080/4885CYP2D6 495/4885 |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | AADAC, TNNI3, TNNT2 | MEN1 1870/4885KMT2A 1482/4885CYP2D6 205/4885 |
| US-20150274719-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | MEN1 2194/4885KMT2A 1080/4885CYP2D6 495/4885 |
| US-20180319794-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | MEN1 2194/4885KMT2A 1080/4885CYP2D6 495/4885 |
| US-20170182014-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | MEN1 2194/4885KMT2A 1080/4885CYP2D6 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.